RAFAEL TAMARGO, M.D.
Medical Practice at Wolfe St, Baltimore, MD

License number
Maryland D41887
Category
Medical Practice
Type
Neurological Surgery
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-6406
(410) 955-6500

Personal information

See more information about RAFAEL TAMARGO at radaris.com
Name
Address
Phone
Rafael Tamargo
5707 Enderly Rd, Baltimore, MD 21212
Rafael Tamargo
5707 Enderly Rd, Baltimore, MD 21212
Rafael Tamargo
2306 Pennyroyal Ter, Baltimore, MD 21209

Professional information

Rafael Tamargo Photo 1

Dr. Rafael Tamargo, Baltimore MD - MD (Doctor of Medicine)

Specialties:
Neurosurgery
Address:
600 N Wolfe St, Baltimore 21287
John Hopkins Hospital Nrsrgry
601 N Caroline St, Baltimore 21287
(410) 955-2257 (Phone)
Certifications:
Neurosurgery, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
600 N Wolfe St, Baltimore 21287
John Hopkins Hospital Nrsrgry
601 N Caroline St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Columbia Univ Coll Of Physicians and Surgeons
Graduated: 1984
Columbia P&S
The Johns Hopkins Hospital


Rafael Jesus Tamargo Photo 2

Rafael Jesus Tamargo, Baltimore MD

Specialties:
Neurological Surgery, Pediatric Neurological Surgery
Work:
Johns Hopkins Outpatient Center
601 N Caroline St, Baltimore, MD 21287 Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD 21224 The Johns Hopkins Hospital
600 N Wolfe St, Baltimore, MD 21287 The Johns Hopkins Hospital
1800 Orleans St, Baltimore, MD 21287
Education:
Columbia University (1984)


Rafael Tamargo Photo 3

Antibiotic Composition For Inhibition Of Angiogenesis

US Patent:
6482810, Nov 19, 2002
Filed:
Apr 13, 1994
Appl. No.:
08/227100
Inventors:
Henry Brem - Lutherville MD 21093
Rafael J. Tamargo - Baltimore MD 21209
Robert A. Bok - Minneapolis MN 55416
International Classification:
A61K 3165
US Classification:
514152
Abstract:
Pharmaceutical compositions for delivering an effective dose of an angiogenesis inhibitor consisting of a tetracycline or tetracycline such as minocycline. The effective dosage for inhibition of angiogenesis based on in vitro testing is between one and 500 micromolar. The compositions are delivered topically, locally or systemically using implants or injection. The composition is extremely selective for growth of endothelial cells, inhibiting growth, but is not cytotoxic at the effective dosages.